"Prasugrel Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
| Descriptor ID |
D000068799
|
| MeSH Number(s) |
D02.886.778.315 D03.383.606.420 D03.383.903.315
|
| Concept/Terms |
LY 640315- LY 640315
- 640315, LY
- LY640315
- LY-640315
|
Below are MeSH descriptors whose meaning is more general than "Prasugrel Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Prasugrel Hydrochloride".
This graph shows the total number of publications written about "Prasugrel Hydrochloride" by people in this website by year, and whether "Prasugrel Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prasugrel Hydrochloride" by people in Profiles.
-
Ijaz SH, Baron SJ, Shahnawaz A, Kulbak G, Levy M, Resnic F, Ganatra S, Dani SS. Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries. Curr Probl Cardiol. 2023 May; 48(5):101608.
-
Gill K, Servati N, Flahive J, Fraielli K. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. J Cardiovasc Pharmacol Ther. 2021 11; 26(6):625-629.
-
Goldsweig AM, Povsic TJ. Complex Percutaneous Coronary Intervention: Discrete Entity or Just Another Subgroup to Analyze? Circ Cardiovasc Interv. 2021 07; 14(7):e010891.
-
Soueid AE, Kassas I, Rade J, Kakouros N. Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study. J Invasive Cardiol. 2021 04; 33(4):E263-E268.
-
Hariri E, Lessard D, Gore J, Rade J, Goldberg R. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction? Cardiovasc Revasc Med. 2020 02; 21(2):182-188.
-
Gerrits AJ, Jakubowski JA, Sugidachi A, Michelson AD, Frelinger AL. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost. 2017 05; 15(5):858-867.
-
Jakubowski JA, Zhou C, Winters KJ, Lachno DR, Howard J, Payne CD, Mant T, Jurcevic S, Frelinger AL. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 2015; 26(5):474-9.
-
Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL, Gupta N, Howard J, Payne CD, Mant TG. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014 Feb; 133(2):190-5.
-
Keaney JF. P2Y12 inhibition in patients with NSTEMI--can later be better? N Engl J Med. 2013 Sep 12; 369(11):1056-7.
-
Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL, Howard J, Mant TG, Jurcevic S, Payne CD. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013 Jun; 75(6):1433-44.